• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The ligand paradox between affinity and efficacy: can you be there and not make a difference?

作者信息

Kenakin Terry, Onaran Ongun

机构信息

7TM Pharmacology, Systems Research, GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709, USA.

出版信息

Trends Pharmacol Sci. 2002 Jun;23(6):275-80. doi: 10.1016/s0165-6147(02)02036-9.

DOI:10.1016/s0165-6147(02)02036-9
PMID:12084633
Abstract

Efficacy is described in terms of the ligand-induced bias of receptor micro-conformations. A virtual simulation of binding of a collection of random ligands can reconcile an apparent paradox in receptor theory, namely the theoretical requirement that affinity and efficacy be related to each other and the experimental fact that medicinal chemistry often can separate structure-activity relationships for affinity and efficacy. The simulation indicates that homoscedacity in the relationship allows for a general correlation with isolated instances of non-compliance. This leads to the conclusion that if a ligand binds to the receptor it will change the receptor by its presence. Therefore, this suggests that all ligands with macro-affinity should be extensively studied for pharmacological activities other than simple G-protein activation with the potential promise of discovering new therapeutic applications for old drugs.

摘要

相似文献

1
The ligand paradox between affinity and efficacy: can you be there and not make a difference?
Trends Pharmacol Sci. 2002 Jun;23(6):275-80. doi: 10.1016/s0165-6147(02)02036-9.
2
Energetics of ligand binding to receptors.配体与受体结合的能量学
J Neural Transm Suppl. 1983;18:55-60.
3
Protein flexibility in ligand docking and virtual screening to protein kinases.用于蛋白激酶的配体对接和虚拟筛选中的蛋白质柔性
J Mol Biol. 2004 Mar 12;337(1):209-25. doi: 10.1016/j.jmb.2004.01.003.
4
The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy.三次三元复合受体占据模型。III. 恢复效能。
J Theor Biol. 1996 Aug 21;181(4):381-97. doi: 10.1006/jtbi.1996.0139.
5
What is pharmacological 'affinity'? Relevance to biased agonism and antagonism.药理学“亲和力”是什么?与偏态激动和拮抗作用的相关性。
Trends Pharmacol Sci. 2014 Sep;35(9):434-41. doi: 10.1016/j.tips.2014.06.003. Epub 2014 Jul 17.
6
Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.从化学角度量化生物活性:描述药物效应的药理学入门知识。
ACS Chem Biol. 2009 Apr 17;4(4):249-60. doi: 10.1021/cb800299s. Epub 2009 Feb 4.
7
Drug efficacy at G protein-coupled receptors.药物在G蛋白偶联受体上的功效。
Annu Rev Pharmacol Toxicol. 2002;42:349-79. doi: 10.1146/annurev.pharmtox.42.091401.113012.
8
Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.使用放射性配体结合和药理学无效方法估算变构配体的亲和力。
Mol Pharmacol. 1988 Feb;33(2):187-94.
9
Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data.解析G蛋白偶联受体的内在活性和配体偏向性:评估功能数据实用指南
Biochem Pharmacol. 2016 Feb 1;101:1-12. doi: 10.1016/j.bcp.2015.10.011. Epub 2015 Oct 23.
10
Systematic exploitation of multiple receptor conformations for virtual ligand screening.系统利用多种受体构象进行虚拟配体筛选。
PLoS One. 2011;6(5):e18845. doi: 10.1371/journal.pone.0018845. Epub 2011 May 17.

引用本文的文献

1
Agonist efficiency links binding and gating in a nicotinic receptor.激动剂效率将烟碱型乙酰胆碱受体的结合和门控联系起来。
Elife. 2023 Jul 3;12:e86496. doi: 10.7554/eLife.86496.
2
Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics.通过结构和动力学研究揭示 M4 毒蕈碱受体变构作用的药理学特征。
Elife. 2023 May 30;12:e83477. doi: 10.7554/eLife.83477.
3
More is simpler: Decomposition of ligand-binding affinity for proteins being disordered.越是复杂越简单:蛋白无规则区域配体结合亲和力的分解。
Protein Sci. 2022 Jul;31(7):e4375. doi: 10.1002/pro.4375.
4
Specific Engineered G Protein Coupling to Histamine Receptors Revealed from Cellular Assay Experiments and Accelerated Molecular Dynamics Simulations.特定工程化的 G 蛋白偶联到组胺受体:细胞分析实验和加速分子动力学模拟的揭示。
Int J Mol Sci. 2021 Sep 17;22(18):10047. doi: 10.3390/ijms221810047.
5
Translating biased signaling in the ghrelin receptor system into differential in vivo functions.将胃饥饿素受体系统中的偏倚信号转导转化为不同的体内功能。
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10255-E10264. doi: 10.1073/pnas.1804003115. Epub 2018 Oct 9.
6
Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.受体拮抗作用/激动作用可与药效伴侣活性解偶联。
Mol Cell Endocrinol. 2016 Oct 15;434:176-85. doi: 10.1016/j.mce.2016.07.003. Epub 2016 Jul 4.
7
Ligand Binding Ensembles Determine Graded Agonist Efficacies at a G Protein-coupled Receptor.配体结合集合决定了G蛋白偶联受体上激动剂的分级效力。
J Biol Chem. 2016 Jul 29;291(31):16375-89. doi: 10.1074/jbc.M116.735431. Epub 2016 Jun 13.
8
The imidazoline receptors and ligands in pain modulation.疼痛调节中的咪唑啉受体与配体
Indian J Pharmacol. 2015 Sep-Oct;47(5):472-8. doi: 10.4103/0253-7613.165196.
9
The mass action equation in pharmacology.药理学中的质量作用方程。
Br J Clin Pharmacol. 2016 Jan;81(1):41-51. doi: 10.1111/bcp.12810. Epub 2015 Dec 21.
10
Re-exploring the N-phenylpicolinamide derivatives to develop mGlu4 ligands with improved affinity and in vitro microsomal stability.重新探索N-苯基吡啶甲酰胺衍生物,以开发具有更高亲和力和体外微粒体稳定性的代谢型谷氨酸受体4(mGlu4)配体。
Bioorg Med Chem Lett. 2015 Sep 15;25(18):3956-60. doi: 10.1016/j.bmcl.2015.07.031. Epub 2015 Jul 17.